Emfizatamab

Emfizatamab (GNC-038) is a monoclonal antibody against CD19/CD3E/TNFRSF9/PD-L1. Emfizatamab exhibits antitumor activity, being capable of activating CD3 and 4-1BB signals on T cells, as well as targeting the high expression of CD19 or PD-L1 on tumor cells. Emfizatamab functions as a CD19-specific T cell engager by mediating direct antitumor activity. Emfizatamab can also overcome the inhibition of T cells by PD-L1. Emfizatamab can be used in the research of tumors such as R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia[1][2].

Product Specifications

CAS Number

[2559704-23-1]

Product Name Alternative

GNC-038

UNSPSC

12352203

Target

CD19; CD3; PD-1/PD-L1; TNF Receptor

Type

Inhibitory Antibodies

Related Pathways

Apoptosis; Immunology/Inflammation

Applications

COVID-19-immunoregulation

Field of Research

Cancer; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/emfizatamab.html

Purity

95.495

Smiles

[Emfizatamab]

Molecular Weight

(303.229 kDa)

References & Citations

[1]Emfizatamab|[2]Wang J, et al. GNC-038, a tetra-specific antibody, in patients with R/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: A phase 1 study design and rationale. 2023.